2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.135 Philip Young NACLC23 Abstract

PP01.135 Philip Young NACLC23 Abstract

Pdf Summary

This study investigated the outcomes and treatment patterns for recurrence in patients with unresectable stage III non-small cell lung cancer (NSCLC) who received concurrent chemoradiation and consolidation immunotherapy. A total of 192 patients were included in the study, with a median follow-up duration of 24.9 months from the start of immunotherapy. The median progression-free survival (PFS) was 16.8 months and the median overall survival (OS) was 36.8 months. <br /><br />Of the 192 patients, 92 (48%) developed recurrence, with 67% experiencing recurrence within 1 year. The subsequent treatment for recurrence varied, including dual immunotherapy, single immunotherapy, platinum doublet chemotherapy, single-agent chemotherapy, concurrent chemoRT, local treatment only, and no treatment. The median PFS2 (time from first progression) was 9.5 months and the median OS2 was 12.1 months. There were no statistically significant differences in PFS2 or OS2 based on the treatment received. Among patients with metastatic recurrence, the median OS2 with systemic therapy was 13.6 months. <br /><br />The study found that there were no statistically significant differences in PFS2 or OS2 between patients with local recurrence and those with metastatic recurrence. The median PFS2 and OS2 were numerically shorter for patients with recurrence within 1 year, but these differences were not statistically significant. <br /><br />Overall, the study suggests that the survival outcomes after recurrence for stage III NSCLC treated with consolidation immunotherapy are shorter than historical controls for newly diagnosed stage IV NSCLC. The results indicate that there is a need for further prospective study to identify optimal treatments for recurrence after stage III treatment.

Keywords

stage III non-small cell lung cancer

recurrence

unresectable

chemoradiation

consolidation immunotherapy

progression-free survival

overall survival

treatment patterns

metastatic recurrence

prospective study